Post-COVID Syndrome: First Patients Enrolled into our COCOS Study
2025-04-01
We are thrilled to announce that the first patients have now been enrolled into the COCOS study!
The COCOS study is a clinical trial investigating the treatment effects of our Ginkgo biloba extract EGb 761® in patients with cognitive impairment associated with post-COVID-19 syndrome.
“COCOS” aims to address the current lack of treatment for cognitive impairment in post-COVID syndrome and contribute to the understanding of EGb 761®, our proprietary dry extract from the leaves of Ginkgo biloba, as a potential treatment for cognitive impairment in post-COVID-19 syndrome.
The study will be conducted in three countries: Germany, Poland, and Spain, with a total of 400 patients planned to participate. We are excitedly awaiting the results in 2026.
Further information on the study can be found at the following link:
Background:
Whilst the acute infection with SARS-CoV-2 viruses has lost its horror, the health impairment of patients with post-COVID syndrome is very burdensome both for those affected and for the healthcare system as a whole. In Europe alone, the number of people affected by post-COVID is estimated at 36 million. Numerous initiatives have been launched to provide better help for those affected through new therapeutic options, but the disease is still poorly understood and there is still no approved therapy available.
More than one-fifth of patients with post-COVID syndrome report cognitive impairment, with attention, memory, or executive functioning deficits. which has a substantial negative impact on daily functioning and quality of life and may lead to significant economic consequences for individuals and society.
The pathophysiology of post-COVID syndrome associated cognitive impairment is not fully understood, but key factors such as neuroinflammation, neurovascular dysfunction, and disruption of cellular energy metabolism have been identified. There are no evidence-based treatments that target the pathologic mechanisms of cognitive impairment associated with PCS, thus current management is directed towards symptom relief.